SUPPLY AGREEMENTSupply Agreement • February 24th, 2021 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • California
This SUPPLY AGREEMENT (“Agreement”) is effective December 22, 2015 (the “Effective Date”), by and between CyDex Pharmaceuticals, Inc., a Delaware corporation with principal offices at 11119 North Torrey Pines Road, Suite 200, La Jolla, California 92037 (“CYDEX”), and Gilead Sciences, Inc., a Delaware corporation with principal offices at 333 Lakeside Drive, Foster City, California 94404 (“Gilead”). CYDEX and Gilead are sometimes referred to individually as “Party” or collectively as the “Parties.”
SECOND CALL OPTION AMENDMENT AGREEMENT dated as of January 28, 2021 Between LIGAND PHARMACEUTICALS INCORPORATED and BARCLAYS BANK PLCSecond Call Option Amendment Agreement • February 24th, 2021 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS SECOND CALL OPTION AMENDMENT AGREEMENT (this “Agreement”) with respect to the Call Option Confirmations (as defined below) is made as of January 28, 2021 between Ligand Pharmaceuticals Incorporated (“Company”) and Barclays Bank PLC (“Dealer”).
SECOND CALL OPTION AMENDMENT AGREEMENT dated as of January 28, 2021 Between LIGAND PHARMACEUTICALS INCORPORATED and DEUTSCHE BANK AG, LONDON BRANCHCall Option Amendment Agreement • February 24th, 2021 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS SECOND CALL OPTION AMENDMENT AGREEMENT (this “Agreement”) with respect to the Call Option Confirmations (as defined below) is made as of January 28, 2021 between Ligand Pharmaceuticals Incorporated (“Company”) and Deutsche Bank AG, London Branch (“Dealer”).
SECOND CALL OPTION AMENDMENT AGREEMENT dated as of January 28, 2021 Between LIGAND PHARMACEUTICALS INCORPORATED and GOLDMAN SACHS & CO. LLCSecond Call Option Amendment Agreement • February 24th, 2021 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS SECOND CALL OPTION AMENDMENT AGREEMENT (this “Agreement”) with respect to the Call Option Confirmations (as defined below) is made as of January 28, 2021 between Ligand Pharmaceuticals Incorporated (“Company”) and Goldman Sachs & Co. LLC (“Dealer”).
